Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 49Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 17Fallopian Tube Neoplasms 17Esophageal Squamous Cell Carcinoma 15Esophageal Neoplasms 15Neoplasms 14Neoplasm Metastasis 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Uterine Cervical Neoplasms 12Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Colorectal Neoplasms 6Carcinoma 6Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Peritoneal Neoplasms 3

Interventions

Radiotherapy 2tislelizumab 1pembrolizumab 1TP protocol 1Paclitaxel 1Lomustine 1Cisplatin 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Recurrence, Local × Paclitaxel × Clear all
NCT06942416 2025-04-24

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
36 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡